
- /
- Supported exchanges
- / F
Intra-Cellular Therapies Inc (23I F) stock market data APIs
Intra-Cellular Therapies Inc Financial Data Overview
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Intra-Cellular Therapies Inc data using free add-ons & libraries
Get Intra-Cellular Therapies Inc Fundamental Data
Intra-Cellular Therapies Inc Fundamental data includes:
- Net Revenue: 614 M
- EBITDA: -121 086 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-09
- EPS/Forecast: -0.79
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Intra-Cellular Therapies Inc News

Steady M&A Deals to Begin 2025, Disappointing IPOs So Far
January is in the books, and markets are still waiting on a big rebound in the dealmaking space. Investors rooting for increased M&A and a flurry of IPOs will have to be patient as Q1 tracks with cont...


Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now
We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025.In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other st...

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now
We recently compiled a list of the Why These 10 Large-Cap Stocks are Skyrocketing.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the ...

Biotech Venture Investors Optimistic, But Uncertainties Persist
Biotechnology venture capital is recovering from its slide and investors are expressing optimism about 2025, even as they confront uncertainties weighing on their industry. Continue Reading View Comments
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.